CN112715873A - Blueberry powder compound solid preparation capable of protecting eyes and improving memory and preparation method and application thereof - Google Patents
Blueberry powder compound solid preparation capable of protecting eyes and improving memory and preparation method and application thereof Download PDFInfo
- Publication number
- CN112715873A CN112715873A CN202011451769.7A CN202011451769A CN112715873A CN 112715873 A CN112715873 A CN 112715873A CN 202011451769 A CN202011451769 A CN 202011451769A CN 112715873 A CN112715873 A CN 112715873A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- blueberry powder
- blueberry
- compound solid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 78
- 235000003095 Vaccinium corymbosum Nutrition 0.000 title claims abstract description 60
- 235000017537 Vaccinium myrtillus Nutrition 0.000 title claims abstract description 60
- 235000021014 blueberries Nutrition 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims abstract description 51
- 150000001875 compounds Chemical class 0.000 title claims abstract description 38
- 239000007787 solid Substances 0.000 title claims abstract description 36
- 230000015654 memory Effects 0.000 title claims abstract description 33
- 244000077233 Vaccinium uliginosum Species 0.000 title description 2
- 240000000851 Vaccinium corymbosum Species 0.000 claims abstract description 58
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract description 42
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 34
- 235000013305 food Nutrition 0.000 claims abstract description 25
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 21
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 21
- 229940026510 theanine Drugs 0.000 claims abstract description 21
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 claims abstract description 20
- 235000012754 curcumin Nutrition 0.000 claims abstract description 17
- 239000004148 curcumin Substances 0.000 claims abstract description 17
- 229940109262 curcumin Drugs 0.000 claims abstract description 17
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 17
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 17
- 244000269722 Thea sinensis Species 0.000 claims abstract description 15
- 238000002156 mixing Methods 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 239000000463 material Substances 0.000 claims abstract description 10
- 230000001954 sterilising effect Effects 0.000 claims description 11
- 238000004659 sterilization and disinfection Methods 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 235000013402 health food Nutrition 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 239000011812 mixed powder Substances 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 3
- 238000007908 dry granulation Methods 0.000 claims description 3
- 238000007689 inspection Methods 0.000 claims description 3
- 238000009928 pasteurization Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 238000005550 wet granulation Methods 0.000 claims description 3
- 244000194101 Ginkgo biloba Species 0.000 claims description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 230000006641 stabilisation Effects 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- 235000020985 whole grains Nutrition 0.000 claims description 2
- 235000013616 tea Nutrition 0.000 claims 9
- 235000011201 Ginkgo Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 235000013373 food additive Nutrition 0.000 abstract description 6
- 239000002778 food additive Substances 0.000 abstract description 6
- 230000033228 biological regulation Effects 0.000 abstract description 2
- 210000004556 brain Anatomy 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000003464 asthenopia Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000013016 learning Effects 0.000 description 5
- 235000010208 anthocyanin Nutrition 0.000 description 4
- 239000004410 anthocyanin Substances 0.000 description 4
- 229930002877 anthocyanin Natural products 0.000 description 4
- 150000004636 anthocyanins Chemical class 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- 239000012752 auxiliary agent Substances 0.000 description 3
- 208000029028 brain injury Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 235000012680 lutein Nutrition 0.000 description 3
- 229960005375 lutein Drugs 0.000 description 3
- 239000001656 lutein Substances 0.000 description 3
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 3
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 241000208421 Ericaceae Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- -1 N-acetylneuraminic acid ganglioside Chemical class 0.000 description 2
- 208000010340 Sleep Deprivation Diseases 0.000 description 2
- 235000012511 Vaccinium Nutrition 0.000 description 2
- 241000736767 Vaccinium Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000037326 chronic stress Effects 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000002270 gangliosides Chemical class 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 241000489492 Arisaema Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 241001233914 Chelidonium majus Species 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 240000000774 Cunila origanoides Species 0.000 description 1
- 235000018274 Cunila origanoides Nutrition 0.000 description 1
- 235000014866 Dictamnus albus Nutrition 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 241000305492 Gastrodia Species 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 240000000759 Lepidium meyenii Species 0.000 description 1
- 235000000421 Lepidium meyenii Nutrition 0.000 description 1
- 241000830535 Ligustrum lucidum Species 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 241001522129 Pinellia Species 0.000 description 1
- 241000018650 Pinus massoniana Species 0.000 description 1
- 235000011610 Pinus tabuliformis Nutrition 0.000 description 1
- 241000208966 Polygala Species 0.000 description 1
- 101000713302 Rattus norvegicus Sodium-coupled neutral amino acid transporter 1 Proteins 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 240000008488 Thlaspi arvense Species 0.000 description 1
- 235000008214 Thlaspi arvense Nutrition 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940055416 blueberry extract Drugs 0.000 description 1
- 235000019216 blueberry extract Nutrition 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 201000006318 hyperopia Diseases 0.000 description 1
- 230000004305 hyperopia Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229940116298 l- malic acid Drugs 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 235000012902 lepidium meyenii Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000019581 neuron apoptotic process Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- 201000010041 presbyopia Diseases 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000014733 refractive error Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/14—Organic oxygen compounds
- A21D2/16—Fatty acid esters
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/24—Organic nitrogen compounds
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/24—Organic nitrogen compounds
- A21D2/245—Amino acids, nucleic acids
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/36—Vegetable material
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/44—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/10—Marmalades; Jams; Jellies; Other similar fruit or vegetable compositions; Simulated fruit products
- A23L21/12—Marmalades; Jams; Jellies; Other similar fruit or vegetable compositions; Simulated fruit products derived from fruit or vegetable solids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- Nutrition Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a blueberry powder compound solid preparation capable of protecting eyes and improving memory and a preparation method and application thereof, the blueberry powder compound solid preparation capable of protecting eyes and improving memory comprises 10-90 parts by weight of blueberry powder, 5-30 parts by weight of lutein ester, 10-70 parts by weight of N-acetylneuraminic acid, 10-90 parts by weight of tea theanine, 0.1-5 parts by weight of curcumin and 10-60 parts by weight of white fruit powder, and the preparation method of the blueberry powder compound solid preparation capable of protecting eyes and improving memory comprises a) mixing, b) granulating, c) crushing and d) post-treatment, all components of the blueberry powder compound solid preparation prepared by the invention are common food, medicinal and edible materials, new food raw material censorship stopping articles, food additives and other articles allowed to eat by laws and regulations, and are suitable for teenagers and middle-aged people, has obvious effects of protecting eyes and improving memory.
Description
[ technical field ] A method for producing a semiconductor device
The invention relates to the technical field of compound solid preparations, in particular to a blueberry powder compound solid preparation capable of protecting eyes and improving memory, and a preparation method and application thereof.
[ background of the invention ]
Asthenopia refers to eye fatigue caused by excessive use of eyes while working or learning at close distances. This condition is often prone to people engaged in close-range precision work or computer work, people who learn or work in environments with poor lighting conditions (over-bright/over-dark light), people with refractive errors such as myopia, hyperopia, and presbyopia, and people with physical weakness. The symptoms of asthenopia include blurred vision after a long time, inability to write or read, dry eyes, dizziness and pain, and nausea in severe cases. Excessive visual cell depletion can lead to increased metabolic waste, accumulation of oxygen radicals, and inadequate supply of ocular nutrients, thus exacerbating asthenopia symptoms.
Visual fatigue is too severe and memory loss occurs. Memory impairment is a common symptom in the elderly, and if there is a lack of effective prevention and treatment, a significant portion of them will develop senile dementia. Through certain intervention means, such as health education, memory training, nutritional health food supplement and the like, the memory capacity of teenagers and middle-aged and elderly people can be improved, so that the learning achievement of the teenagers is improved, and the life quality of the elderly people is improved.
With the improvement of health consciousness of the national people in China, self-care mainly based on prevention, health care, healthy living style, healthy living environment and the like is taken as a core, and the idea of taking disease treatment as an auxiliary is continuously strengthened. The trend of nutrition and health care towards food is a future development trend, and the market demand is huge. The nutritional health-care safe food which is required by different people and is prepared by adopting common food, medicinal and edible food, new food raw materials, food additives and the like as raw and auxiliary materials has become necessary requirements of consumers.
Chinese patent publication No. CN108619399A discloses a compound preparation for protecting eyes and improving eyesight and a preparation method thereof, wherein the compound preparation is prepared by mixing glossy privet fruit, fennel fruit, ginger processed pinellia tuber, celandine, acanthopanax root, tall gastrodia tuber, Indian buead, dittany bark, pennycress, arisaema tuber, Chinese pine nodular branch, lutein and blueberry according to a certain proportion. The patent adopts a large amount of Chinese herbal medicine compound components, can not be eaten as common food, and has unclear toxic and side effects after long-term eating.
Chinese patent publication No. CN107410633A discloses a production technology of a tabletting hard candy with eye-protecting and brain-strengthening effects, which is prepared by mixing defatted perilla powder, inulin, xylitol, lutein and blueberry extract according to a certain proportion and tabletting. The patent is prepared from food raw and auxiliary materials, has a certain eye protection effect, but has a very slight brain strengthening effect, and can not give consideration to the eye protection and brain strengthening nutrition differentiation requirements of teenagers and old people.
Chinese patent with publication number CN106581204A discloses a Chinese herbal compound extract for assisting in improving memory, which is prepared by mixing maca, polygala root and spina date seed according to a certain proportion. The patent adopts special compound components for health-care food, can not be eaten as common food, and has no obvious effect on assisting in improving memory.
[ summary of the invention ]
The invention aims to solve the problems in the prior art, provides a blueberry powder compound solid preparation capable of protecting eyes and improving memory, and a preparation method and application thereof, is suitable for teenagers and middle-aged and elderly people, and has obvious effects of protecting eyes and improving memory.
In order to achieve the purpose, the invention is realized by the following technical scheme:
a blueberry powder compound solid preparation capable of protecting eyes and improving memory comprises, by weight, 10-90 parts of blueberry powder, 5-30 parts of lutein ester, 10-70 parts of N-acetylneuraminic acid, 10-90 parts of tea theanine, 0.1-5 parts of curcumin and 10-60 parts of white fruit powder.
Preferably, the blueberry powder comprises, by weight, 40-90 parts of blueberry powder, 10-25 parts of lutein ester, 50-70 parts of N-acetylneuraminic acid, 40-80 parts of theanine, 0.25-5 parts of curcumin and 30-60 parts of white fruit powder.
Preferably, the ginkgo biloba extract comprises 40 parts by weight of blueberry powder, 15 parts by weight of lutein ester, 50 parts by weight of N-acetylneuraminic acid, 40 parts by weight of tea theanine, 0.25 part by weight of curcumin and 35 parts by weight of ginkgo biloba powder.
Preferably, the blueberry powder comprises 80 parts by weight of blueberry powder, 25 parts by weight of lutein ester, 70 parts by weight of N-acetylneuraminic acid, 70 parts by weight of tea theanine, 2 parts by weight of curcumin and 60 parts by weight of white fruit powder.
Preferably, the blueberry powder comprises 90 parts by weight of blueberry powder, 15 parts by weight of lutein ester, 50 parts by weight of N-acetylneuraminic acid, 80 parts by weight of tea theanine, 5 parts by weight of curcumin and 30 parts by weight of white fruit powder.
A preparation method of a blueberry powder compound solid preparation capable of protecting eyes and improving memory comprises the following steps:
a) mixing: weighing 10-90 parts of blueberry powder, 5-30 parts of lutein ester, 10-70 parts of N-acetylneuraminic acid, 10-90 parts of theanine, 0.1-5 parts of curcumin and 10-60 parts of white fruit powder in parts by weight, and putting into a mixing container to be uniformly mixed to obtain mixed powder;
b) and (3) granulation: carrying out wet granulation or dry granulation and size stabilization on the mixed powder obtained in the step a) to obtain mixed particles;
c) crushing: drying, crushing and sieving the mixed particles obtained in the step b) at low temperature to obtain screened powder;
d) and (3) post-treatment: removing metal foreign matters in the screened powder obtained in the step c), carrying out metal detection inspection after internal packaging, then sterilizing, and carrying out external packaging to obtain a finished product.
Preferably, in the step b), the number of the whole grains is 10 to 30.
Preferably, in the step c), the screening mesh number is 80-120 meshes, and the drying temperature is lower than 50 ℃.
Preferably, in the step d), the sterilization mode adopts ultra-high pressure sterilization, pasteurization or irradiation sterilization.
An application of a blueberry powder compound solid preparation capable of protecting eyes and improving memory is characterized in that the blueberry powder compound solid preparation capable of protecting eyes and improving memory is used as a main raw material or an auxiliary material and is added into common food, health food or medicines.
The general food, health food or medicine includes, but is not limited to, tablets, capsules, granules, oral liquid, hard candy, gel candy, solid beverage, liquid beverage, jelly, baked food, cake, etc.
The anthocyanin contained in the blueberry powder can effectively improve the activity of superoxide dismutase, glutathione peroxidase and the like of photodamaged retinal cells and the total protein content, and obviously reduce the content of malondialdehyde. In addition, by observation of histopathology, blueberry anthocyanin can protect cells of each layer of retina completely, improve damaged cells and increase the thickness of an outer nucleus layer of retina. Therefore, the blueberry anthocyanin has a remarkable protective effect on retinal photodamage.
Anthocyanin contained in the blueberry powder can obviously improve learning and memory disorder and influence NF-kB signal transduction pathway, thereby inhibiting oxidative stress and inflammatory reaction, reducing lipofuscin accumulation in brain tissue, improving antioxidant function and regulating and controlling the expression of cognition related protein in nervous system.
Researches show that blue light in nature and on a display screen is a main cause of damage to a macular area of a retina of a human eye. Blue light has higher energy and can induce the mass generation of reactive oxygen species, thereby directly damaging retinal nerve cells. The lutein ester is a main component forming the macular pigment of the human eye, mainly plays a role in filtering blue light, and simultaneously can quench singlet oxygen, control the generation of active oxygen clusters, and reduce the oxidation caused by illumination. The intake of the food rich in lutein ester can increase the content of lutein in tissues, and plays an important role in preventing and protecting age-related macular degeneration.
N-acetylneuraminic acid plays an important role in the growth and development of the nervous system and brain, is an important component of ganglioside, and is also involved in synaptic transmission. The exogenous supply of N-acetylneuraminic acid can increase the concentration of ganglioside in brain, and improve learning ability, especially cognitive level.
There is a correlation between the composition of N-acetylneuraminic acid in the brain and the growth of nerve cells and the extension of processes. In the blood or brain of some patients with neurological diseases such as senile dementia, incipient wetness and schizophrenia, the content of N-acetylneuraminic acid is obviously reduced, but the content is gradually normal along with the development of rehabilitation therapy. The N-acetylneuraminic acid ganglioside has obvious effects on treating cerebral ischemia, Parkinson's disease, senile dementia and nerve trauma.
Theanine can pass through brain barrier and has certain protection effect on neuronal damage caused by transient ischemia of brain. The structural similarity of theanine, which is a neurotransmitter related to memory, determines its specific role in the nervous system. Theanine can strongly act on glutamine transporters, thereby inhibiting the concerted transport of glutamine outside cells to neurons, and finally inhibiting the conversion of glutamine into glutamic acid.
Theanine not only reverses cognitive impairment due to chronic stress, alleviates oxidative damage due to chronic stress, but also restores abnormal levels of corticosterone and catecholamine in the plasma and brain. Therefore, theanine also has a good protective effect on cognitive impairment caused by chronic restraint stress.
The sleep has the functions of promoting growth and development, maintaining individual survival, forming memory and the like. Sleep deprivation refers to a series of changes in learning, memory, mood, and immune functions caused by failure to satisfy normal sleep due to its own or environmental causes, accompanied by changes in mind, physiology, and even behavior caused by increased fatigue. Curcumin can protect the sleep-deprived cardiac muscle tissue by improving the oxidation resistance of the cardiac muscle tissue, reducing the level of inflammatory factors, relieving oxidative stress injury and other mechanisms, and plays a role in inhibiting inflammatory reaction through a TLR 4/NF-KB signal channel, thereby effectively improving the cognitive function of sleep deprivation.
The bilobalide can promote neuron autophagy, inhibit neuron apoptosis, relieve acute phase tissue lesion and nerve dysfunction caused by ischemic brain injury, improve ischemic brain injury, convalescent phase nerve motor function, promote convalescent phase tissue repair, and promote proliferation and differentiation of neural stem cells, thereby promoting recovery phase function improvement of ischemic brain injury and endogenous nerve regeneration level.
The invention has the beneficial effects that:
1) all components of the blueberry powder compound solid preparation prepared by the invention are common food, medicinal and edible substances, new food raw materials, new food raw material censorship stopping substances, food additives and other substances which are allowed to be eaten by laws and regulations;
2) the mechanisms of eyesight and memory deterioration of the teenagers and the middle-aged and the elderly are common and different, the blueberry powder compound solid preparation prepared by the invention is suitable for the teenagers and the elderly, and has obvious effects on protecting eyes and improving memory;
3) the blueberry powder compound solid preparation prepared by the invention has no toxic or side effect, is not suitable for infants and pregnant women, and is suitable for various people of different age groups, different physiques and different health conditions;
4) the blueberry powder compound solid preparation prepared by the invention can be used as a raw material or an auxiliary material, and can be prepared into various foods, health-care foods and medicines such as tablets, capsules, granules, oral liquid, hard candies, gel candies, solid beverages, liquid beverages, jellies, baked foods, cakes and the like.
The features and advantages of the present invention will be described in detail by embodiments in conjunction with the accompanying drawings.
[ description of the drawings ]
Fig. 1 is a flow chart of preparation and application of a blueberry powder compound solid preparation.
[ detailed description ] embodiments
The first embodiment is as follows:
weighing 40 parts of blueberry powder, 15 parts of lutein ester, 50 parts of N-acetylneuraminic acid, 40 parts of tea theanine, 0.25 part of curcumin and 35 parts of white fruit powder according to the weight ratio, putting into a mixing container, and uniformly mixing to obtain mixed powder. Subsequently, the obtained mixed powder was subjected to wet granulation or dry granulation and size adjustment to obtain a mixed granule with a mesh size of 10 meshes. Subsequently, the obtained mixed granules were subjected to low-temperature drying at less than 50 ℃, pulverization and sieving, and the mesh number was 120 to obtain a sieved powder. And finally, removing metal foreign matters in the obtained screened powder by an iron remover, carrying out metal detection and inspection after carrying out inner packaging by adopting a food-grade or medicinal-grade PE bag, then carrying out sterilization by adopting an ultrahigh pressure sterilization mode, and carrying out outer packaging to obtain a finished product.
The blueberry powder is prepared by using wild or artificially-planted Ericaceae (Eri-caceae) and Vaccinium spp (Vaccinium spp) blueberry fruits as raw materials, performing pretreatment, extracting (optionally skipping the extraction step), filtering to remove residues, separating and concentrating the filtrate by column chromatography (optionally skipping the separation and concentration step by column chromatography), adding maltodextrin (optionally adding maltodextrin), drying and the like.
The finished product obtained in the steps can be used as a raw material, and can be prepared into common food, health food or medicines after adding a proper amount of auxiliary materials such as food additives, auxiliary agents and the like.
For example, 60 parts of energy-free sweetener and 50 parts of microcrystalline cellulose are added into a blueberry powder compound solid preparation finished product, uniformly mixed and directly filled to prepare hard capsules, granules, powder or solid beverages and the like; ② adding 60 parts of non-energy sweetener, 50 parts of microcrystalline cellulose and 50 parts of magnesium stearate in weight proportion into the finished blueberry powder compound solid preparation, mixing uniformly, and pressing into tablets, tabletting candies, hard candies and the like.
Example two:
weighing 80 parts of blueberry powder, 25 parts of lutein ester, 70 parts of N-acetylneuraminic acid, 70 parts of tea theanine, 2 parts of curcumin and 60 parts of white fruit powder.
The number of the screened meshes is 100 meshes, the sterilization mode is hot water pasteurization, and the other steps are the same as the first embodiment.
The finished product obtained in the steps can be used as a raw material, and can be prepared into common food, health food or medicines after adding a proper amount of auxiliary materials such as food additives, auxiliary agents and the like.
For example, 20 parts by weight of purified water is added into a hot water heating jacket stirring tank and heated to 50 ℃, 34 parts by weight of glycerin fatty acid ester and 250 parts by weight of corn oil are added into a blueberry powder compound solid preparation finished product, after the mixture is uniformly mixed, the mixture is put into the tank and continuously stirred, 168 parts by weight of gelatin is added, after the gelatin is completely dissolved, the mixture is continuously added with 62 parts by weight of glycerin and finally uniformly stirred to serve as a gelatin sandwich material, and a soft capsule, a sugar-free gel candy, a sugar-free jelly, a sugar-free sandwich gel candy, a jam, a baking sauce and the like are prepared on a machine.
Example three:
weighing 90 parts of blueberry powder, 15 parts of lutein ester, 50 parts of N-acetylneuraminic acid, 80 parts of tea theanine, 5 parts of curcumin and 30 parts of white fruit powder.
The number of the screening meshes is 80, and the other steps are the same as those of the first embodiment.
The finished product obtained in the steps can be used as a raw material, and can be prepared into common food, health food or medicines after adding a proper amount of auxiliary materials such as food additives, auxiliary agents and the like.
For example, 1100 parts by weight of purified water is added into a hot water heating jacket stirring tank and heated to 38 ℃, 30 parts by weight of modified soybean lecithin, 15 parts by weight of potassium alginate and 15 parts by weight of magnesium carbonate are added into a blueberry powder compound solid preparation finished product, after the mixture is uniformly mixed, the mixture is added into the tank and is continuously stirred, then 120 parts by weight of non-energetic sweetener, 50 parts by weight of citric acid and 50 parts by weight of L-malic acid are weighed, and are dissolved by 500 parts by weight of purified water and then are added into the tank, the mixture is uniformly stirred, and finally the mixture is filled to prepare oral liquid, liquid beverage and the like.
The above embodiments are illustrative of the present invention, and are not intended to limit the present invention, and any simple modifications of the present invention are within the scope of the present invention.
Claims (10)
1. A blueberry powder compound solid preparation capable of protecting eyes and improving memory is characterized in that: the blueberry and tea leaf tea beverage comprises, by weight, 10-90 parts of blueberry powder, 5-30 parts of lutein ester, 10-70 parts of N-acetylneuraminic acid, 10-90 parts of tea theanine, 0.1-5 parts of curcumin and 10-60 parts of white fruit powder.
2. The compound solid preparation of blueberry powder capable of protecting eyes and improving memory as claimed in claim 1, wherein: the blueberry and tea leaf tea beverage comprises, by weight, 40-90 parts of blueberry powder, 10-25 parts of lutein ester, 50-70 parts of N-acetylneuraminic acid, 40-80 parts of tea theanine, 0.25-5 parts of curcumin and 30-60 parts of white fruit powder.
3. The compound solid preparation of blueberry powder capable of protecting eyes and improving memory as claimed in claim 2, wherein: comprises 40 parts of blueberry powder, 15 parts of lutein ester, 50 parts of N-acetylneuraminic acid, 40 parts of tea theanine, 0.25 part of curcumin and 35 parts of ginkgo powder in parts by weight.
4. The compound solid preparation of blueberry powder capable of protecting eyes and improving memory as claimed in claim 2, wherein: comprises 80 parts of blueberry powder, 25 parts of lutein ester, 70 parts of N-acetylneuraminic acid, 70 parts of tea theanine, 2 parts of curcumin and 60 parts of white fruit powder.
5. The compound solid preparation of blueberry powder capable of protecting eyes and improving memory as claimed in claim 2, wherein: comprises 90 parts of blueberry powder, 15 parts of lutein ester, 50 parts of N-acetylneuraminic acid, 80 parts of tea theanine, 5 parts of curcumin and 30 parts of white fruit powder.
6. A preparation method of a blueberry powder compound solid preparation capable of protecting eyes and improving memory is characterized by comprising the following steps:
a) mixing: weighing 10-90 parts of blueberry powder, 5-30 parts of lutein ester, 10-70 parts of N-acetylneuraminic acid, 10-90 parts of theanine, 0.1-5 parts of curcumin and 10-60 parts of white fruit powder in parts by weight, and putting into a mixing container to be uniformly mixed to obtain mixed powder;
b) and (3) granulation: carrying out wet granulation or dry granulation and size stabilization on the mixed powder obtained in the step a) to obtain mixed particles;
c) crushing: drying, crushing and sieving the mixed particles obtained in the step b) at low temperature to obtain screened powder;
d) and (3) post-treatment: removing metal foreign matters in the screened powder obtained in the step c), carrying out metal detection inspection after internal packaging, then sterilizing, and carrying out external packaging to obtain a finished product.
7. The preparation method of the blueberry powder compound solid preparation capable of protecting eyes and improving memory as claimed in claim 6, wherein the preparation method comprises the following steps: in the step b), the number of the whole grains is 10-30 meshes.
8. The preparation method of the blueberry powder compound solid preparation capable of protecting eyes and improving memory as claimed in claim 6, wherein the preparation method comprises the following steps: in the step c), the screening mesh number is 80-120 meshes, and the drying temperature is lower than 50 ℃.
9. The preparation method of the blueberry powder compound solid preparation capable of protecting eyes and improving memory as claimed in claim 6, wherein the preparation method comprises the following steps: in the step d), the sterilization mode adopts ultrahigh pressure sterilization, pasteurization or irradiation sterilization.
10. The application of the blueberry powder compound solid preparation capable of protecting eyes and improving memory is characterized in that: the blueberry powder compound solid preparation capable of protecting eyes and improving memory as claimed in claim 1 is added into common food, health food or medicines as a main raw material or an auxiliary material.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011451769.7A CN112715873A (en) | 2020-12-10 | 2020-12-10 | Blueberry powder compound solid preparation capable of protecting eyes and improving memory and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011451769.7A CN112715873A (en) | 2020-12-10 | 2020-12-10 | Blueberry powder compound solid preparation capable of protecting eyes and improving memory and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112715873A true CN112715873A (en) | 2021-04-30 |
Family
ID=75599458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011451769.7A Pending CN112715873A (en) | 2020-12-10 | 2020-12-10 | Blueberry powder compound solid preparation capable of protecting eyes and improving memory and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112715873A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111227097A (en) * | 2020-02-27 | 2020-06-05 | 山东祥宏堂医药有限公司 | Blueberry lutein ester candy tablet and preparation method thereof |
CN111616221A (en) * | 2020-07-03 | 2020-09-04 | 北安宜品努卡乳业有限公司 | Milk powder for improving memory and relieving pressure and preparation method thereof |
-
2020
- 2020-12-10 CN CN202011451769.7A patent/CN112715873A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111227097A (en) * | 2020-02-27 | 2020-06-05 | 山东祥宏堂医药有限公司 | Blueberry lutein ester candy tablet and preparation method thereof |
CN111616221A (en) * | 2020-07-03 | 2020-09-04 | 北安宜品努卡乳业有限公司 | Milk powder for improving memory and relieving pressure and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
徐文兵, 北京:中国中医药出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108112762B (en) | Novel functional soft sweet and preparation method thereof | |
CN101766307B (en) | Health food with function of relieving visual fatigue and preparation method thereof | |
CN102742656B (en) | Milky tea relieving asthenopia and preparation method thereof | |
EP2138055B1 (en) | Formula food to be beneficial for visuognosis persistence and use thereof | |
CN107837288A (en) | A kind of compound anthocyanidin lutein ester soft capsule for alleviating visual fatigue | |
US20160151437A1 (en) | Nutritional supplements for improved vision and methods of treating the same | |
CN100574772C (en) | A kind of soft capsule that contains phylloxanthin and preparation method thereof | |
CN112568397A (en) | Blueberry powder compound solid preparation capable of improving sleep and preparation method and application thereof | |
CN111528421A (en) | Eye-protecting product containing plant exosomes and preparation method thereof | |
CN108159036A (en) | Composition for relieving asthenopia containing theanine, phosphatidylserine and procyanidine | |
CN117562255A (en) | Composition for relieving visual fatigue and preparation method thereof | |
CN100486456C (en) | Health-care food used for reliefing eyestrain, and its preparing method | |
CN102894435B (en) | Mulberry-medlar leaf beverage with function of asthenopia relieving | |
CN106692187A (en) | Composition for improving visuognosis persistence and protecting eye health | |
CN108354918A (en) | Composition for relieving asthenopia containing theanine, γ-aminobutyric acid and procyanidine | |
CN101757299A (en) | Product for relieving visual fatigue and preparation method thereof | |
CN111227231A (en) | Composite blueberry lutein ester powder and preparation method thereof | |
CN109619189A (en) | A kind of black fruit Sorbus alnifloria eye protecting milk tablet of sea-buckthorn and preparation method thereof | |
CN112715873A (en) | Blueberry powder compound solid preparation capable of protecting eyes and improving memory and preparation method and application thereof | |
CN115251217A (en) | Visual fatigue relieving tabletting candy as well as preparation method and application thereof | |
JP2004035510A (en) | Composition for prophylaxis or treatment of diabetes mellitus or its complication | |
CN115956670A (en) | Composition and preparation for relieving visual fatigue, preparation method and application | |
CN112042939A (en) | Chewable tablet for supplementing retina nutrition | |
JP2020202882A (en) | Green tea-containing food and drink for maintaining or recovering motivation or concentration | |
CN108354143A (en) | Composition for relieving asthenopia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210430 |